Review
Biochemistry & Molecular Biology
Hannah L. Tumbrink, Alena Heimsoeth, Martin L. Sos
Summary: EGFR mutations play a major role in druggable targets for lung adenocarcinoma, and optimization of EGFR inhibitors has significantly impacted treatment options. However, the emergence of resistance mutations during drug treatment has driven the need for rapid understanding of individual mutations for developing next-generation inhibitors. The field currently faces a large number of combinations of activating mutations and distinct resistance mutations, alongside the approval of osimertinib as a frontline drug for EGFR-mutant lung cancer.
Article
Immunology
Jing Pan, Donghai Xiong, Qi Zhang, Katie Palen, Robert H. H. Shoemaker, Bryon Johnson, Shizuko Sei, Yian Wang, Ming You
Summary: In this study, immunogenic epitopes for common EGFR mutations in humans were identified and a multi-peptide vaccine (E-mut Vax) targeting these mutations was formulated. The E-mut Vax effectively prevented EGFR mutation-driven lung tumorigenesis in mouse models and enhanced Th1 responses in the tumor microenvironment while decreasing suppressive Tregs.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Kenichi Suda, Kazuko Sakai, Tatsuo Ohira, Takaaki Chikugo, Takao Satou, Jun Matsubayashi, Toshitaka Nagao, Norihiko Ikeda, Yasuhiro Tsutani, Tetsuya Mitsudomi, Kazuto Nishio
Summary: Genetic information is crucial before the treatment of NSCLC. This study compares the performance of Idylla EGFR Mutation Test with Cobas EGFR Mutation Test v2 and demonstrates the accuracy of Idylla EGFR Mutation Test as a molecular screening platform. Proposed genetic testing strategies may reduce costs and shorten the turnaround time.
Article
Medical Informatics
Shuo Wang, He Yu, Yuncui Gan, Zhangjie Wu, Encheng Li, Xiaohu Li, Jingxue Cao, Yongbei Zhu, Liusu Wang, Hui Deng, Mei Xie, Yuanyong Wang, Xidong Ma, Dan Liu, Bojiang Chen, Panwen Tian, Zhixin Qiu, Jinghong Xian, Jing Ren, Kun Wang, Wei Wei, Fei Xie, Zhenhui Li, Qi Wang, Xinying Xue, Zaiyi Liu, Jingyun Shi, Weimin Li, Jie Tian
Summary: This study introduced a fully automated artificial intelligence system (FAIS) that mined whole-lung information from CT images to predict EGFR genotype and prognosis with EGFR-TKI treatment. FAIS outperformed tumour-based deep learning models, providing a non-invasive method to detect EGFR genotype and identify high-risk EGFR mutation patients for TKI resistance.
LANCET DIGITAL HEALTH
(2022)
Article
Pharmacology & Pharmacy
Haoyue Hu, Songtao Tan, Meng Xie, Peng Guo, Qiang Yu, Juan Xiao, Kangrui Zhao, Qiong Liao, Yi Wang
Summary: In non-small cell lung cancer, concurrent genetic alterations of epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements are rare, but their clinical and pathological characteristics are not well-defined, and the optimal treatment approach remains controversial. This report presents a case of stage IV lung adenocarcinoma with both EGFR and ALK mutations, along with high PD-L1 expression. The patient initially received treatment with EGFR tyrosine kinase inhibitors (TKIs), but the disease progressed, and regression was achieved following a switch to ALK-TKI therapy and local radiotherapy. Our report also provides a comprehensive summary of the clinical and pathological features, as well as treatment strategies, for NSCLC patients with concurrent EGFR mutation and ALK rearrangement.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Oncology
Ruiyuan Yang, Xingyu Xiong, Haoyu Wang, Weimin Li
Summary: The objective of this study is to determine if clinical features and blood markers can establish an explainable machine learning model to predict EGFR mutation in lung cancer. The researchers analyzed data using various machine learning algorithms and identified key features for prediction. The study showed promising results and highlighted the importance of artificial intelligence in diagnosing and treating lung cancer.
FRONTIERS IN ONCOLOGY
(2022)
Review
Oncology
Minghui Liu, Xiaoyu Niu, Hongyu Liu, Jun Chen
Summary: This study summarized the common germline mutations of EGFR in lung cancer, including T790M, V843I, R776H, and P848L, and provided detailed information about each mutation site and potential treatment strategies. The study recommends regular physical examinations and population-wide germline mutation screening for early detection and diagnosis of lung cancer.
Review
Biochemical Research Methods
Katerina Ondraskova, Ravery Sebuyoya, Ludmila Moranova, Jitka Holcakova, Petr Vonka, Roman Hrstka, Martin Bartosik
Summary: This review highlights the importance of DNA point mutations in cancer and discusses commonly used screening methods. It also explores the advantages and challenges of electrochemical biosensors as a potential alternative technology.
ANALYTICAL AND BIOANALYTICAL CHEMISTRY
(2023)
Article
Oncology
Takashi Ito, Hiromi Nagashima, Masachika Akiyama, Yu Utsumi, Hideomi Sato, Shinji Chiba, Mayu Sugai, Kenji Ube, Yoshiaki Mori, Kana Watanabe, Tatsuro Fukuhara, Makoto Maemondo
Summary: EGFR-mutated NSCLC patients with L858R mutation are more likely to respond well to ICI treatment. The occurrence of T790M resistance mutation before ICI treatment did not differ significantly between different response groups. Patients with shorter duration of EGFR-TKI pretreatment are more likely to respond well to ICI treatment.
Article
Oncology
Xiaotong Qiu, Yong Wang, Fen Liu, Lihong Peng, Chen Fang, Xiaoyin Qian, Xinwei Zhang, Qian Wang, Zhehao Xiao, Renfang Chen, Shangkun Yuan, Yong Li
Summary: Studies have shown that non-small cell lung cancer patients with EGFR mutations, but with concurrent PIK3CA mutations, treated with EGFR-TKIs have a shorter time to progression and lower overall survival rates.
AMERICAN JOURNAL OF CANCER RESEARCH
(2021)
Article
Oncology
Chaelin Lee, Miso Kim, Dong-Wan Kim, Tae Min Kim, Soyeon Kim, Sun-Wha Im, Yoon Kyung Jeon, Bhumsuk Keam, Ja-Lok Ku, Dae Seog Heo
Summary: This study reveals that the T790M mutation in EGFR-KDD confers resistance to 1st and 2nd generation EGFR tyrosine kinase inhibitors (TKIs), but is sensitive to 3rd generation EGFR TKIs. In addition, the study identifies that the C797S mutation in kinase domain 2 of EGFR-KDDT790M mediates a resistance mechanism against 3rd generation EGFR TKIs.
CANCER RESEARCH AND TREATMENT
(2022)
Article
Biochemistry & Molecular Biology
Lyudmila V. Bel'skaya, Elena A. Sarf, Denis V. Solomatin, Victor K. Kosenok
Summary: The study aimed to compare the metabolic characteristics of salivary composition in lung cancer, COPD, and their combination with respect to smoking history. Different groups of biochemical saliva markers are informative when separately considering smoking and COPD in lung cancer. Specifically, markers corresponding to the presence/absence and severity of COPD are prioritized when taking smoking history.
Review
Oncology
Dan Yan, H. Shelton Earp, Deborah DeRyckere, Douglas K. Graham
Summary: MERTK and AXL are abnormally expressed in the majority of NSCLCs, providing a survival advantage for cells and correlating with metastasis, drug resistance, and disease progression. Host tumor infiltrating cells' TAM receptors also play crucial roles in the immunosuppressive tumor microenvironment. These factors make MERTK and AXL attractive targets for NSCLC treatment.
Article
Oncology
Misako Nagasaka, Vijendra Singh, Yasmine Baca, Ammar Sukari, Chul Kim, Hirva Mamdani, Alexander Spira, Dipesh Uprety, Gerold Bepler, Edward S. Kim, Luis E. Raez, Sachin Gopalkrishna Pai, Chukwuemeka Ikpeazu, Matthew Oberley, Rebecca Feldman, Joanne Xiu, W. Michael Korn, Antoinette J. Wozniak, Hossein Borghaei, Stephen Liu
Summary: HER2 alterations can lead to resistance to EGFR tyrosine kinase inhibitors in NSCLC patients. Among the 12,946 samples analyzed, 2.5% had HER2 alterations, with 1.5% of EGFR mutated patients also having concurrent HER2 alterations. Patients with both EGFR mutation and HER2 amplification had longer time on treatment with EGFR TKIs compared to those with EGFR mutation alone. It is important to continue gathering clinical data for further analysis of real-world outcomes.
CLINICAL LUNG CANCER
(2022)
Article
Oncology
Chunxiang Li, Yalong Wang, Kai Su, Yu Liu, Liyu Wang, Bo Zheng, Na Yan, Dawei Yuan, Yanxiang Zhang, Liyan Xue, Shugeng Gao, Jie He
Summary: The study identified unique EGFR mutation signatures in a large cohort of MPLC probands, including both germline and somatic mutations. Some patients harbored multiple mutations, and certain mutations had significantly higher occurrence rates in MPLC probands compared to patients with sporadic LUAD.
TRANSLATIONAL LUNG CANCER RESEARCH
(2021)
Article
Oncology
Szu-Chun Yang, Chin-Wei Kuo, Wu-Wei Lai, Chien-Chung Lin, Wu-Chou Su, Sheng-Mao Chang, Jung-Der Wang
JOURNAL OF THORACIC ONCOLOGY
(2019)
Article
Pathology
Michael Tu, Jordan Cheng, Yi-Lin Chen, Wen-Chien Jea, Wan-Li Chen, Chien-Jung Chen, Chung-Liang Ho, Wei-Lun Huang, Chien-Chung Lin, Wu-Chou Su, Qianlin Ye, Josh Deignan, Wayne Grody, Feng Li, David Chia, Fang Wei, Wei Liao, David T. W. Wong, Charles M. Strom
JOURNAL OF MOLECULAR DIAGNOSTICS
(2020)
Article
Oncology
Feng Li, Fang Wei, Wei-Lun Huang, Chien-Chung Lin, Liang Li, Macy M. Shen, Qingxiang Yan, Wei Liao, David Chia, Michael Tu, Jason H. Tang, Ziding Feng, Yong Kim, Wu-Chou Su, David T. W. Wong
Editorial Material
Oncology
Chang-Yao Chu, Hong-Ping Er, Chien-Chung Lin
Article
Oncology
Po-Lan Su, Chian-Wei Chen, Yi-Lin Wu, Chien-Chung Lin, Wu-Chou Su
Summary: This study compared the efficacy of afatinib, erlotinib, and gefitinib in EGFR mutation-positive advanced NSCLC patients. Results indicated that afatinib resulted in significantly better overall survival and progression-free survival in patients without brain metastases.
Article
Biochemistry & Molecular Biology
Chien-Chung Lin, Chin-You Wu, Joseph Ta-Chien Tseng, Chun-Hua Hung, Shang-Yin Wu, Yu-Ting Huang, Wei-Yuan Chang, Po-Lan Su, Wu-Chou Su
Summary: Intratumoral heterogeneity in EGFR-mutant NSCLC explains mixed responses to EGFR-TKIs. Analyses of EVs revealed that EV miRNAs can impact tumor cells' sensitivity to EGFR-TKIs, offering potential prognostic biomarkers for EGFR-mutant NSCLC.
Article
Medicine, General & Internal
Jeng-Shiuan Tsai, Po-Lan Su, Szu-Chun Yang, Chao-Chun Chang, Chia-Ying Lin, Yi-Ting Yen, Yau-Lin Tseng, Wu-Wei Lai, Chien-Chung Lin, Wu-Chou Su
Summary: Real-world data analysis demonstrates that the combination of EGFR-TKI and bevacizumab improves progression-free survival (PFS) in patients with EGFR-mutant non-small cell lung cancer, with better overall survival (OS) observed in patients harboring the L858R mutation.
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION
(2021)
Article
Environmental Sciences
Szu-Chun Yang, Ching-Han Lai, Chin-Wei Kuo, Chien-Chung Lin, Wu-Wei Lai, Jung-Der Wang
Summary: This study aimed to estimate downstream complications and healthcare expenditure after invasive lung procedures in Taiwan. Results showed that non-lung cancer individuals aged 50-80 years had higher complication rates and costs within one month.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
(2021)
Article
Oncology
Po-Lan Su, Jeng-Shiuan Tsai, Szu-Chun Yang, Yi-Lin Wu, Yau-Lin Tseng, Chao-Chun Chang, Yi-Ting Yen, Chia-Ying Lin, Chien-Chung Lin, Chin-Chou Wang, Meng-Chih Lin, Wu-Chou Su
Summary: Osimertinib-based combination therapy showed better overall survival for NSCLC patients with disease progression after osimertinib treatment, supported by synergism with chemotherapy and a higher proportion of apoptosis cells. These findings suggest the potential benefit of osimertinib-based combination therapy and warrant further validation in randomized controlled studies.
Article
Oncology
Jason C. Hsu, Phung-Anh Nguyen, Yen-Tzu Chen, Szu-Chun Yang, Chien-Chung Lin, Yi-Hsin Yang, Yu-Chao Lin, Te-Chun Hsia, Hsing-Chun Hsieh, Jia-Syuan Wu, Chi-Pei Chang, Yin-Hsun Feng, Peng-Chan Lin, Ping-Chih Hsu, Huey-En Tzeng, Shu-Chen Chien, Wei-Chiao Chang, Chih-Cheng Chang, Hsuan-Chia Yang, Chueh Ming Lee, Christine Y. Lu
Summary: The study investigated the effectiveness and safety of ICIs in treating non-small cell lung cancer patients, finding no significant difference in overall survival between ICIs and traditional chemotherapy groups, but a lower incidence of serious adverse drug events in the ICIs group. Higher levels of PD-L1 were associated with longer overall survival in patients.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Sheng-Yuan Wang, Ching-Han Lai, Chian-Wei Chen, Szu-Chun Yang, Chao-Chun Chang, Chia-Ying Lin, Yi-Ting Yen, Yau-Lin Tseng, Po-Lan Su, Chien-Chung Lin, Wu-Chou Su
Summary: This study compared different treatment strategies for unresectable stage III EGFR-mutant adenocarcinoma patients and found that upfront EGFR-TKIs may lead to longer progression-free and overall survival compared to upfront concurrent chemoradiotherapy. Further randomized studies are needed to validate these results.
Article
Oncology
Chi-Hao Wu, Po-Lan Su, Che-Wei Hsu, Chang-Yao Chu, Chien-Chung Lin
Summary: ROS1 rearrangement is a significant factor in non-small cell lung cancer (NSCLC). Small cell transformation plays a role in ROS1 resistance, emphasizing the importance of tissue biopsy for patients with ROS1 TKI resistance.
Article
Oncology
Shi-Ming Tu, Sunny R. Singh, Konstantinos Arnaoutakis, Sindhu Malapati, Sajjad A. Bhatti, Aron Y. Joon, Omar T. Atiq, Louis L. Pisters
Summary: This article discusses the application of the stem cell theory of cancer in cancer research and care. By amending translational research and emphasizing the scientific method, the theory has the potential to enhance cancer research and improve patient care. It considers the genetic makeup of cancer in relation to cellular context and microenvironment.
Article
Chemistry, Medicinal
Jeng-Shiuan Tsai, Sheng-Huan Wei, Chian-Wei Chen, Szu-Chun Yang, Yau-Lin Tseng, Po-Lan Su, Chien-Chung Lin, Wu-Chou Su
Summary: This study compares the treatment efficacy of immune checkpoint inhibitors (ICIs) monotherapy with combination therapy in patients with advanced non-small cell lung cancer (NSCLC). The results show that combination therapy provides a better progression-free survival (PFS), especially in patients with low neutrophil-to-lymphocyte ratio (NLR).
Article
Oncology
Lecia V. Sequist, James Chih-Hsin Yang, Nobuyuki Yamamoto, Kenneth O'Byrne, Vera Hirsh, Tony Mok, Sarayut Lucien Geater, Sergey Orlov, Chun-Ming Tsai, Michael Boyer, Wu-Chou Su, Jaafar Bennouna, Terufumi Kato, Vera Gorbunova, Ki Hyeong Lee, Riyaz Shah, Dan Massey, Victoria Zazulina, Mehdi Shahidi, Martin Schuler
Summary: The study compared the efficacy of chemotherapy with afatinib in the treatment of EGFR-mutated lung adenocarcinoma. Results showed that afatinib prolonged progression-free survival and improved the quality of life for patients, when compared with chemotherapy.
JOURNAL OF CLINICAL ONCOLOGY
(2023)